Wall Street Zen Downgrades KORU Medical Systems (NASDAQ:KRMD) to Buy

KORU Medical Systems (NASDAQ:KRMD) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

KRMD has been the subject of a number of other reports. Canaccord Genuity Group restated a “buy” rating and issued a $6.00 price target on shares of KORU Medical Systems in a research note on Friday. Craig Hallum reissued a “buy” rating and issued a $7.00 price objective on shares of KORU Medical Systems in a report on Tuesday, January 13th. B. Riley Financial raised their target price on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Thursday, January 22nd. Finally, Lake Street Capital boosted their target price on shares of KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $6.50.

KORU Medical Systems Trading Down 0.7%

KORU Medical Systems stock opened at $4.28 on Friday. The company has a market cap of $198.25 million, a price-to-earnings ratio of -71.33 and a beta of 0.47. The firm has a 50-day moving average of $5.10 and a 200-day moving average of $4.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.48 and a quick ratio of 1.92. KORU Medical Systems has a one year low of $1.86 and a one year high of $6.61.

KORU Medical Systems (NASDAQ:KRMD) last released its earnings results on Thursday, March 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. KORU Medical Systems had a negative return on equity of 16.04% and a negative net margin of 6.41%.The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $10.90 million. On average, equities analysts expect that KORU Medical Systems will post -0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Lakewood Asset Management LLC raised its stake in KORU Medical Systems by 2.8% in the 4th quarter. Lakewood Asset Management LLC now owns 73,945 shares of the company’s stock valued at $430,000 after acquiring an additional 2,000 shares during the period. BNP Paribas Financial Markets boosted its position in KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after purchasing an additional 3,478 shares during the period. White Pine Capital LLC increased its holdings in shares of KORU Medical Systems by 1.6% in the second quarter. White Pine Capital LLC now owns 225,425 shares of the company’s stock valued at $807,000 after purchasing an additional 3,526 shares during the last quarter. Barclays PLC increased its holdings in shares of KORU Medical Systems by 8.8% in the fourth quarter. Barclays PLC now owns 67,442 shares of the company’s stock valued at $392,000 after purchasing an additional 5,457 shares during the last quarter. Finally, Invesco Ltd. raised its position in shares of KORU Medical Systems by 24.8% in the fourth quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock valued at $162,000 after purchasing an additional 5,546 shares during the period. 58.60% of the stock is currently owned by institutional investors.

Trending Headlines about KORU Medical Systems

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: B. Riley raised its price target to $8.00 and maintained a “buy” rating, implying roughly an 87% upside from the current price — a meaningful vote of confidence from a major dealer. Benzinga
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” rating and set a $6.00 target (≈40% upside), adding further analyst support for upside to the stock. Benzinga
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — clear regulatory progress that should aid European commercialization and recurring revenue potential. Las Vegas Sun
• Positive Sentiment: Q4 2025 results beat EPS expectations (loss of $0.01 vs. -$0.02 est.), reported ~20% revenue growth and positive adjusted EBITDA; management also initiated FY2026 guidance with revenue of $47.5M–$50.0M (roughly in line with consensus ~ $48.8M). These operational improvements support medium-term growth prospects. Business Wire – Q4 & Guidance
• Neutral Sentiment: Analysts and the company provided forward revenue guidance but EPS guidance detail was not clearly disclosed in public summaries; revenue range is encouraging but leaves some near-term visibility questions. Q4 Press Release / Slide Deck
• Negative Sentiment: KORU announced a CEO transition: long-time CEO Linda Tharby will retire June 30 and the board appointed Adam Kalberma as successor. Leadership changes introduce short-term execution risk and can pressure the stock until the market judges the new CEO. Business Wire – CEO Transition
• Negative Sentiment: Despite positives, KRMD still shows a negative net margin and negative ROE; valuation and profitability concerns may keep selling pressure, which likely explains why the stock is trading lower even after upgrades and regulatory wins.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.